What is the best second-line treatment for immune thrombocytopenia? Academic Article uri icon

Overview

abstract

  • The choice between thrombopoietin receptor agonists (TPO-RAs) and anti-CD20 as the preferred second-line therapies for immune thrombocytopenia remains in the eye of the beholders. Each has major advantages and certain weaknesses. Stolz et al. describe a single-centre experience that whets our appetite for a large randomized controlled trial comparing a TPO agonist and an anti-CD20 agent. Commentary on: Stolz et al. Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia - A single center retrospective analysis. Br J Haematol 2024; 205:1121-1125.

publication date

  • October 1, 2024

Research

keywords

  • Purpura, Thrombocytopenic, Idiopathic
  • Receptors, Thrombopoietin
  • Rituximab

Identity

Scopus Document Identifier

  • 85206635538

Digital Object Identifier (DOI)

  • 10.1111/bjh.19777

PubMed ID

  • 39415321

Additional Document Info

volume

  • 205

issue

  • 4